Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Qiagen ( (QGEN) ) is now available.
Qiagen N.V. has announced a notification from the Netherlands Authority for the Financial Markets (AFM) regarding its institution, disclosing significant voting rights held by BlackRock, Inc. The notification specifies that BlackRock holds a 10.01% voting rights interest in Qiagen, primarily through indirect real holdings. This disclosure is important for stakeholders as it highlights the influence of a major financial entity within Qiagen’s shareholder structure, potentially impacting corporate governance and decision-making processes.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, specializing in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Qiagen is headquartered in Venlo, Netherlands, and is listed on stock exchanges including the NYSE and several European markets.
YTD Price Performance: 0.94%
Average Trading Volume: 871,740
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $9.93B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.